erlotinib hydrochloride has been researched along with muramidase in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (muramidase) | Trials (muramidase) | Recent Studies (post-2010) (muramidase) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 23,777 | 207 | 5,249 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dolman, ME; Fretz, MM; Goldschmeding, R; Hennink, WE; Kok, RJ; Lacombe, M; Nguyen, TQ; Pato, J; Prakash, J; Storm, G | 1 |
| Arora, N; Gavya S, L; Ghosh, SS | 1 |
2 other study(ies) available for erlotinib hydrochloride and muramidase
| Article | Year |
|---|---|
Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors.
Topics: Cells, Cultured; Chemistry, Pharmaceutical; Drug Carriers; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Kinetics; Muramidase; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2008 |
Multi-facet implications of PEGylated lysozyme stabilized-silver nanoclusters loaded recombinant PTEN cargo in cancer theranostics.
Topics: Antineoplastic Agents; Cell Proliferation; Disease Transmission, Infectious; Erlotinib Hydrochloride; Flow Cytometry; Humans; MCF-7 Cells; Microscopy, Confocal; Models, Biological; Muramidase; Neoplasms; PTEN Phosphohydrolase; Silver; Spectrometry, Fluorescence; Theranostic Nanomedicine | 2018 |